State Street® SPDR® S&P® PhrmctlsETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
State Street® SPDR® S&P® Pharmaceuticals ETF XPH
Morningstar’s Analysis XPH
Will XPH outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 26.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Xeris Biopharma Holdings Inc | 2.68 | 12M | Healthcare |
Veradermics Inc | 2.64 | 12M | Healthcare |
Pacira BioSciences Inc | 2.58 | 12M | Healthcare |
Eli Lilly and Co | 2.54 | 12M | Healthcare |
Amneal Pharmaceuticals Inc Ordinary Shares - Class A | 2.41 | 11M | Healthcare |
Zoetis Inc Class A | 2.30 | 11M | Healthcare |
Viatris Inc | 2.30 | 11M | Healthcare |
Pfizer Inc | 2.24 | 10M | Healthcare |
Maze Therapeutics Inc | 2.23 | 10M | Healthcare |
Perrigo Co PLC | 2.23 | 10M | Healthcare |